ENPP1 and hypophosphatasia: We orally administered 30 and 100 mg/kg/day of an ENPP1 inhibitor, REV102, to the AlplPrx1/- mouse model of late-onset HPP, for 105 days and confirmed target engagement, as plasma PPi concentrations were markedly reduced.